Artivion Inc. logo

Artivion Inc.

AORT | NYSE
Chart Builder DCF Calculator
$23.43
+$0.08 (+0.34%)
Sep 21, 2026, 3:06 PM ET · Market open

Company Profile

Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.

Key Executives

Name Position
James Patrick Mackin Chairman, President & Chief Executive Officer
Lance A. Berry EVice President, Chief Operating Officer, Chief Financial Officer & Treasurer
Amy D. Horton Vice President & Chief Accounting Officer
Andrew Green Senior Vice President of Regulatory & Quality
Jason D. Asper Senior Vice President and Chief Strategy & Digital Officer
Jean F. Holloway Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary
John E. Davis Senior Vice President & Chief Commercial Officer
Matthew A. Getz Vice President of Human Resources & Chief Human Resources Officer
Robert C. Thomson Vice President of Research & Development
Simona Zannetti Senior Vice President of Clinical Research & Chief Medical Officer

Latest SEC Filings

Date Type Title
Sep 04, 2026 4 Filing
Aug 20, 2026 4 Filing
Aug 17, 2026 4 Filing
Aug 17, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 12, 2026 4 Filing
Aug 07, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Aug 06, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jun 15, 2026 4 Filing
View All SEC Filings
Artivion Inc.
Artivion Inc. logo
Country United States
IPO Date Feb 11, 1993
Industry Medical - Devices
Sector Healthcare
Employees 1,800
CEO James Patrick Mackin

Contact Details

1655 Roberts Boulevard N.W. Kennesaw, Georgia 30144 United States

Stock Details

Ticker Symbol AORT
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000784199
CUSIP Number 228903100
ISIN Number US2289031005
SIC Code 3841

© 2026 bestshares.com. All rights reserved.